The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Indications/Uses
Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
